Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors

被引:27
作者
Hao, Miao [1 ,2 ]
Wang, Wei [3 ]
Zhao, Yuqing [4 ]
Zhang, Ruiwen [3 ]
Wang, Hui [1 ,2 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai 200031, Peoples R China
[2] Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China
[3] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Canc Biol Ctr,Dept Pharmaceut Sci, Amarillo, TX 79106 USA
[4] Shenyang Pharmaceut Univ, Shenyang 110016, Peoples R China
关键词
25-hydroxyprotopanaxadiol; Panax ginseng; Pancreatic cancer; Pharmacokinetics; Tissue distribution; SOLID-PHASE EXTRACTION; PERFORMANCE LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; OVARIAN-CANCER; RAT PLASMA; CELLS; RG3; PROLIFERATION; GINSENOSIDES; NOTOGINSENG;
D O I
10.1007/s13318-010-0022-9
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
To determine pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol [25-OH-PPD, 20(R)-dammarane-3 beta,12 beta,20,25-tetrol], a promising antitumor natural product isolated from the fruits of Panax ginseng, an analytical method involving liquid chromatography/tandem mass spectrometry in biological samples was developed and employed. After intravenous and oral administration to nude mice bearing xenografts of human pancreatic tumors at doses of 10 and 20 mg/kg body weight, respectively, 25-OH-PPD was rapidly absorbed and distributed in plasma and in all tissues examined, including the tumors, with all C-max > 2 mu g/ml or mu g/g and t(max) < 1 h. The absolute oral bioavailability of 25-OH-PPD was relatively high, compared with other ginsenosides. These results indicate that this novel anti-cancer ginsenoside has relatively favorable pharmacokinetic properties and provide a basis for further development of this compound as a chemotherapeutic agent.
引用
收藏
页码:109 / 113
页数:5
相关论文
共 29 条
[1]
Ginseng pharmacology - Multiple constituents and multiple actions [J].
Attele, AS ;
Wu, JA ;
Yuan, CS .
BIOCHEMICAL PHARMACOLOGY, 1999, 58 (11) :1685-1693
[2]
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[3]
Panax ginseng - A systematic review of adverse effects and drug interactions [J].
Coon, JT ;
Ernst, E .
DRUG SAFETY, 2002, 25 (05) :323-344
[4]
Analysis methods of ginsenosides [J].
Fuzzati, N .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 812 (1-2) :119-133
[5]
Proof of the mysterious efficacy of ginseng: Basic and clinical trials: Metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid [J].
Hasegawa, H .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 95 (02) :153-157
[6]
Helms Steve, 2004, Altern Med Rev, V9, P259
[7]
Cancer statistics, 2007 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Murray, Taylor ;
Xu, Jiaquan ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66
[8]
Jia WWG, 2004, CAN J PHYSIOL PHARM, V82, P431, DOI [10.1139/y04-049, 10.1139/Y04-049]
[9]
Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells [J].
Kim, HS ;
Lee, EH ;
Ko, SR ;
Choi, KJ ;
Park, JH ;
Im, DS .
ARCHIVES OF PHARMACAL RESEARCH, 2004, 27 (04) :429-435
[10]
Ginsenoside 20(S)-protopanaxadiol inhibits the proliferation and invasion of human fibrosarcoma HT1080 cells [J].
Li, Gang ;
Wang, Zhenhua ;
Sun, Yaxuan ;
Liu, Ke ;
Wang, Ziren .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (06) :588-592